Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18421847 | SUSPENSION CULTURE OF HUMAN EMBRYONIC STEM CELLS | January 2024 | June 2025 | Allow | 17 | 3 | 0 | Yes | No |
| 18417981 | METHODS OF PROCESSING MUNICIPAL SOLID WASTE (MSW) USING MICROBIAL HYDROLYSIS AND FERMENTATION | January 2024 | April 2025 | Abandon | 15 | 0 | 1 | No | No |
| 18409148 | METHOD FOR QUANTIFYING AT LEAST ONE MICROORGANISM GROUP VIA MASS SPECTROMETRY | January 2024 | June 2025 | Allow | 17 | 1 | 1 | No | No |
| 18513988 | Treatment Method and Product for Uterine Fibroids using Purified Collagenase | November 2023 | December 2025 | Abandon | 25 | 2 | 0 | No | No |
| 18498391 | COMPOSITIONS AND METHODS FOR INHIBITING THE PROLIFERATION OF ENTEROTOXIGENIC BACTEROIDES FRAGILIS | October 2023 | February 2025 | Allow | 16 | 1 | 0 | No | No |
| 18498455 | COMPOSITIONS AND METHODS FOR INHIBITING THE PROLIFERATION OF ENTEROTOXIGENIC BACTEROIDES FRAGILIS | October 2023 | March 2025 | Allow | 16 | 1 | 0 | No | No |
| 18381795 | COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES AND MAINTAINING HEALTHY SKIN | October 2023 | July 2025 | Abandon | 20 | 1 | 1 | No | No |
| 18490521 | COMPOSITIONS AND METHODS FOR INHIBITING THE PROLIFERATION OF ENTEROTOXIGENIC BACTEROIDES FRAGILIS | October 2023 | February 2025 | Allow | 16 | 1 | 0 | No | No |
| 18458388 | PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE | August 2023 | January 2025 | Allow | 17 | 1 | 0 | No | No |
| 18446136 | CULTURE MEDIUM COMPOSITION | August 2023 | December 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18214335 | EXOSOMAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE | June 2023 | January 2025 | Allow | 19 | 2 | 1 | No | No |
| 18323578 | METHODS AND COMPOSITIONS FOR ATTENUATING ANTIBIOTIC RESISTANCE | May 2023 | March 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18199442 | METHOD FOR PRODUCING THERAPEUTIC EXOSOMES FROM NANOELECTROPORATION AND OTHER NON-ENDOCYTIC CELL TRANSFECTION | May 2023 | April 2025 | Allow | 23 | 1 | 1 | Yes | No |
| 18318877 | METHOD FOR TREATING HEART FAILURE | May 2023 | January 2025 | Allow | 20 | 1 | 0 | No | No |
| 18308531 | CAPTURE, PURIFICATION, AND RELEASE OF BIOLOGICAL SUBSTANCES USING A SURFACE COATING | April 2023 | March 2025 | Abandon | 23 | 1 | 1 | No | No |
| 18129593 | EXOSOMAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE | March 2023 | June 2025 | Abandon | 27 | 2 | 1 | No | No |
| 18181504 | OPTIMIZED INDIVIDUALIZED PREBIOTIC COMPOSITIONS | March 2023 | February 2025 | Abandon | 23 | 1 | 1 | No | No |
| 18112242 | ROSEBURIA HOMINIS, EUBACTERIUM ELIGENS, AND COMBINATIONS THEREOF AS BIOTHERAPEUTICS | February 2023 | February 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18020518 | A METHOD FOR THE EARLY DETECTION OF POTATO BACTERIAL DISEASES BASED ON CHARACTERIZING VOLATILE SIGNATURES | February 2023 | January 2026 | Abandon | 35 | 0 | 1 | No | No |
| 18010371 | SURFACTANT PREPARATION PROCESS | December 2022 | November 2025 | Allow | 35 | 1 | 1 | No | No |
| 18062221 | BIFIDOBACTERIUM LONGUM ABLE TO BENEFICIALLY MODULATE IMMUNE RESPONSE TO RESPIRATORY VIRUS INFECTION | December 2022 | November 2024 | Abandon | 23 | 1 | 0 | No | No |
| 18072256 | SYNTHETIC QUORUM-REGULATED LYSIS | November 2022 | November 2024 | Abandon | 24 | 1 | 0 | No | No |
| 18057483 | METHODS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN AND ADOLESCENTS | November 2022 | April 2025 | Abandon | 29 | 2 | 0 | No | No |
| 17988448 | BACILLUS AMYLOLIQUEFACIENS FCC1256 COMPOSITIONS AND METHODS OF CONTROLLING PLANT PATHOGENS | November 2022 | December 2024 | Allow | 25 | 2 | 0 | No | No |
| 17964905 | PREVENTION OF PROGRESSIVE HEART FAILURE | October 2022 | August 2024 | Allow | 22 | 1 | 0 | No | No |
| 18045705 | HORSESHOE CRAB FACTOR B VARIANT | October 2022 | October 2025 | Allow | 36 | 1 | 1 | No | No |
| 17935874 | NON-CLEAVABLE SUBSTANCE P CONJUGATES AND METHODS OF USE THEREOF | September 2022 | March 2025 | Abandon | 30 | 3 | 1 | Yes | No |
| 17943462 | METHODS OF TREATING RETINAL DISEASES | September 2022 | August 2025 | Abandon | 35 | 2 | 0 | No | Yes |
| 17942930 | COMPOSITIONS AND METHODS OF PROMOTING CELLULAR HYDRATION | September 2022 | June 2025 | Abandon | 33 | 2 | 1 | No | No |
| 17897731 | SYSTEM AND METHOD FOR DETECTION AND DISPOSAL OF MICROORGANISMS AND DETECTION MODULE DISPOSED IN A WATER FLOW POINT | August 2022 | July 2025 | Abandon | 35 | 3 | 0 | Yes | No |
| 17897711 | SYSTEM AND METHOD FOR DETECTION AND DISPOSAL OF MICROORGANISMS AND DETECTION MODULE DISPOSED IN A WATER FLOW POINT | August 2022 | May 2025 | Abandon | 32 | 3 | 0 | Yes | No |
| 17897754 | SYSTEM AND METHOD FOR DETECTION AND DISPOSAL OF MICROORGANISMS AND DETECTION MODULE DISPOSED IN A WATER FLOW POINT | August 2022 | July 2025 | Abandon | 35 | 3 | 0 | No | No |
| 17796228 | HYALURONIDASE COMPOSITIONS AND METHODS OF USING SAME TO TREAT FIBROSIS | July 2022 | July 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17813931 | COMPOSITIONS AND METHODS FOR AUGMENTING THE NASAL MICROBIOME | July 2022 | July 2023 | Allow | 12 | 0 | 0 | No | No |
| 17793015 | ANTRODIA CINNAMOMEA CULTIVATION METHOD AND POROUS CARRIER FOR CULTIVATING ANTRODIA CINNAMOMEA | July 2022 | September 2025 | Allow | 38 | 2 | 0 | Yes | No |
| 17860723 | SYNERGISTIC COMBINATION OF THERMOLYSIN AND AN ANTIBACTERIAL AGENT TO REDUCE OR ELIMINATE BACTERIAL BIOFILMS FROM SURFACES | July 2022 | December 2023 | Allow | 17 | 1 | 0 | No | No |
| 17846130 | METHODS OF TREATING SPINAL CORD INJURY | June 2022 | May 2024 | Allow | 23 | 1 | 0 | No | No |
| 17830742 | RNA AFFINITY PURIFICATION | June 2022 | July 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17751513 | ACARICIDES | May 2022 | August 2024 | Abandon | 27 | 2 | 0 | No | No |
| 17746210 | ENHANCED ANTIVIRULENT FOR ANTIBIOTIC-RESISTANT BACTERIA | May 2022 | August 2024 | Abandon | 27 | 1 | 1 | No | No |
| 17740837 | Preparation Method of Surimi-Low-Molecular-Weight Antifreeze Peptide | May 2022 | January 2025 | Abandon | 32 | 3 | 0 | No | No |
| 17736854 | PHAGE DELIVERY OF ANTI-INFLAMMATORY PEPTIDES | May 2022 | July 2024 | Abandon | 26 | 1 | 1 | No | No |
| 17674770 | FREEZE-DRIED PLATELET DERIVATIVE COMPOSITIONS FOR TREATING ANTIPLATELET INDUCED COAGULOPATHY | February 2022 | June 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17671308 | Glycan Sample Preparation | February 2022 | March 2024 | Allow | 25 | 1 | 1 | No | No |
| 17590457 | RAPID ANTIMICROBIAL SUSCEPTIBILITY TESTING BY VIDEO-BASED OBJECT SCATTERING INTENSITY DETECTION | February 2022 | March 2024 | Allow | 26 | 1 | 1 | No | No |
| 17631647 | METHODS FOR IMPROVING TITER AND PURITY OF BETA CAROTENE FERMENTATION IN BLAKESLEA TRISPORA (BETA-CAROTENE FERMENTATION METHOD) | January 2022 | December 2024 | Allow | 34 | 1 | 0 | No | No |
| 17585781 | METHODS FOR DETECTION OF SILVER NANOPARTICLES | January 2022 | February 2024 | Allow | 25 | 2 | 0 | Yes | No |
| 17583775 | COMPOSITIONS AND METHODS FOR TREATING IMMUNE DISORDERS USING IMMUNE MODULATING LACTOCOCCUS BACTERIA STRAINS | January 2022 | December 2023 | Abandon | 23 | 1 | 0 | No | No |
| 17552743 | RPE CELL POPULATIONS AND METHODS OF GENERATING SAME | December 2021 | December 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17644606 | MICRONIZED PLACENTAL TISSUE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | December 2021 | November 2023 | Allow | 23 | 1 | 0 | No | No |
| 17546013 | RPE CELL POPULATIONS AND METHODS OF GENERATING SAME | December 2021 | March 2024 | Allow | 27 | 4 | 0 | No | No |
| 17546011 | RPE CELL POPULATIONS AND METHODS OF GENERATING SAME | December 2021 | September 2023 | Abandon | 21 | 3 | 0 | No | No |
| 17534663 | PROLINE TOLERANT TRIPEPTIDYL PEPTIDASES AND USES THEREOF | November 2021 | December 2023 | Abandon | 25 | 0 | 1 | No | No |
| 17505209 | CELL CULTURE CASSETTES AND INCUBATOR | October 2021 | April 2025 | Abandon | 42 | 4 | 0 | No | No |
| 17487532 | BIOSYNTHETIC PRODUCTION OF UDP-RHAMNOSE | September 2021 | July 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17480166 | UNGLYCOSYLATED LYSOSTAPHIN VARIANT PROTEIN | September 2021 | March 2024 | Allow | 30 | 1 | 1 | No | No |
| 17478133 | ANTICANCER COMBINATIONS | September 2021 | September 2023 | Abandon | 24 | 0 | 1 | No | No |
| 17443968 | PEPTIDE MARKERS FOR AUTHENTICATION OF EDIBLE BIRD'S NEST AND RELATED PRODUCTS | July 2021 | August 2025 | Abandon | 49 | 4 | 1 | No | Yes |
| 17422924 | Encapsulated Cells | July 2021 | December 2023 | Abandon | 29 | 0 | 1 | No | No |
| 17354208 | PROBIOTIC (BACILLUS SUBTILIS) SUPPLEMENTATION FOR IMPROVEMENT OF BODY COMPOSITION IN FEMALE ATHLETES | June 2021 | January 2024 | Allow | 31 | 3 | 0 | No | Yes |
| 17348468 | COMPOSITION AND KITS FOR PSEUDOPLASTIC MICROGEL MATRICES | June 2021 | December 2022 | Allow | 18 | 3 | 1 | Yes | No |
| 17323441 | RPE CELL POPULATIONS AND METHODS OF GENERATING SAME | May 2021 | September 2023 | Abandon | 28 | 0 | 1 | No | No |
| 17294300 | DEVICE FOR PRODUCING MICROALGAE | May 2021 | October 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17227287 | COMPOSITIONS AND METHODS FOR INHIBITING THE PROLIFERATION OF ENTEROTOXIGENIC BACTEROIDES FRAGILIS | April 2021 | April 2024 | Abandon | 36 | 2 | 1 | No | No |
| 17227286 | COMPOSITIONS AND METHODS FOR INHIBITING THE PROLIFERATION OF ENTEROTOXIGENIC BACTEROIDES FRAGILIS | April 2021 | April 2024 | Abandon | 36 | 2 | 1 | No | No |
| 17227284 | COMPOSITIONS AND METHODS FOR INHIBITING THE PROLIFERATION OF ENTEROTOXIGENIC BACTEROIDES FRAGILIS | April 2021 | April 2024 | Abandon | 36 | 2 | 1 | No | No |
| 17222222 | Treatment Method and Product for Uterine Fibroids using Purified Collagenase | April 2021 | August 2023 | Allow | 29 | 1 | 0 | No | No |
| 17122521 | COMPOSITIONS AND METHODS OF ENHANCING ANTI-TUMOR RESPONSE USING HYBRID NEUTROPHILS | December 2020 | November 2023 | Allow | 35 | 1 | 1 | No | No |
| 17057831 | PROCESS FOR THE SEPARATION AND PURIFICATION OF PHYCOBILIPROTEINS | November 2020 | November 2025 | Abandon | 60 | 3 | 0 | No | No |
| 17093154 | METHODS AND MATERIALS FOR USING BIOMARKERS WHICH PREDICT SUSCEPTIBILITY TO CLOSTRIDIUM DIFFICILE INFECTION | November 2020 | August 2023 | Allow | 33 | 1 | 0 | No | No |
| 17092154 | USE OF BACILLUS METHYLOTROPHICUS AS A STIMULANT OF PLANT GROWTH AND BIOLOGICAL CONTROL MEANS, AND ISOLATES OF SAID SPECIES | November 2020 | December 2024 | Abandon | 50 | 3 | 1 | No | No |
| 17064126 | Treatment Method and Product for Uterine Fibroids using Purified Collagenase | October 2020 | July 2025 | Abandon | 57 | 6 | 0 | No | No |
| 17026005 | COMPOSITIONS AND METHODS OF FAS INHIBITION | September 2020 | January 2025 | Abandon | 52 | 1 | 1 | Yes | No |
| 17019392 | UPGRADING AND ENRICHMENT OF GASES THROUGH ALGAE PHOTOBIOREACTORS | September 2020 | August 2023 | Allow | 35 | 2 | 0 | No | No |
| 16978674 | METHOD FOR PRODUCING CLAM ACTIVE PEPTIDE | September 2020 | December 2024 | Abandon | 51 | 2 | 1 | No | No |
| 17010642 | PROBIOTICS AND METHODS OF OBTAINING SAME | September 2020 | June 2025 | Abandon | 58 | 4 | 0 | No | No |
| 16943928 | MICROBIAL CONSORTIUM FOR ENHANCING THE METHANE PRODUCTION FROM FEEDSTOCK | July 2020 | April 2025 | Allow | 56 | 6 | 1 | Yes | No |
| 16941206 | METHODS AND DEVICES FOR CELL DETECTION | July 2020 | May 2023 | Abandon | 33 | 1 | 0 | No | No |
| 16963173 | Polypeptides with Asparaginase Activity, Related Compositions, and Methods of Use Thereof | July 2020 | August 2024 | Allow | 49 | 1 | 1 | No | No |
| 16932674 | Methods for the Use of Low-Dose Immune Modulators Transiently for Treating Patients Undergoing Protein Replacement Therapy | July 2020 | November 2023 | Abandon | 40 | 4 | 0 | No | No |
| 16923634 | SYSTEM AND METHOD FOR DETECTION AND DISPOSAL OF MICROORGANISMS AND DETECTION MODULE DISPOSED IN A WATER FLOW POINT | July 2020 | April 2025 | Abandon | 57 | 6 | 1 | Yes | No |
| 16954667 | ANIMAL FEED COMPOSITIONS COMPRISING MURAMIDASE AND USES THEREOF | June 2020 | November 2023 | Abandon | 41 | 2 | 1 | No | No |
| 16901984 | PREPARATION COMPRISING ARABINOXYLO-OLIGOSACCHARIDES | June 2020 | July 2023 | Abandon | 37 | 2 | 0 | No | No |
| 16892543 | GCNT2/I-BRANCHING AS A BIOMARKER OF MELANOMA PROGRESSION | June 2020 | August 2025 | Abandon | 60 | 8 | 1 | Yes | No |
| 16891136 | AUTOFLOCCULATION OF ALGAL BIOMASS | June 2020 | April 2023 | Abandon | 35 | 2 | 0 | No | No |
| 16767948 | METHODS OF INCREASING BIOMASS PRODUCTIVITY IN ALGAE CULTURES | May 2020 | July 2023 | Allow | 38 | 3 | 1 | Yes | No |
| 16883297 | Methods and Compositions for the Prevention and Treatment of Influenza | May 2020 | June 2023 | Abandon | 37 | 2 | 1 | No | No |
| 16875142 | TISSUE-SPECIFIC DIFFERENTIATION MATRICES AND USES THEREOF | May 2020 | January 2023 | Abandon | 32 | 1 | 0 | No | No |
| 16864641 | COMBINATION THERAPIES FOR CANCER | May 2020 | October 2023 | Abandon | 42 | 0 | 1 | No | No |
| 16857965 | ASSESSING AND TREATING FUNCTIONAL GASTROINTESTINAL DISORDERS | April 2020 | September 2023 | Allow | 40 | 2 | 1 | No | No |
| 16852959 | Use of gingival fibroblasts in the treatment of alopecia | April 2020 | February 2022 | Abandon | 22 | 1 | 0 | No | No |
| 16756699 | A Method of Preparing a Pluripotent Stem Cell Suitable for Differentiating into a Cardiomyocyte | April 2020 | March 2023 | Abandon | 35 | 0 | 1 | No | No |
| 16850727 | CALCIUM CONTROLLED ACTIVATION OF PLATELETS VIA ELECTRICAL STIMULATION | April 2020 | October 2022 | Allow | 30 | 1 | 1 | No | No |
| 16850587 | LACTOBACILLUS HAVING ANTIMICROBIAL EFFECT ON GARDNERELLA VAGINALIS AND CANDIDA ALBICANS | April 2020 | September 2023 | Allow | 41 | 2 | 1 | No | No |
| 16841631 | COMPOSITIONS AND METHODS OF PROMOTING CELLULAR HYDRATION | April 2020 | October 2022 | Abandon | 30 | 4 | 1 | Yes | No |
| 16753117 | PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE | April 2020 | May 2023 | Allow | 38 | 1 | 1 | No | No |
| 16832396 | CAPTURE, PURIFICATION, AND RELEASE OF BIOLOGICAL SUBSTANCES USING A SURFACE COATING | March 2020 | January 2023 | Allow | 34 | 2 | 1 | Yes | No |
| 16806527 | METHOD OF MYCELIATING AN AGRICULTURAL SUBSTRATE | March 2020 | July 2024 | Abandon | 53 | 5 | 0 | No | No |
| 16796391 | METHOD TO IMPROVE SAFETY AND EFFICACY OF ANTI-CANCER THERAPY | February 2020 | May 2024 | Abandon | 51 | 4 | 1 | No | No |
| 16636615 | ROSEBURIA HOMINIS, EUBACTERIUM ELIGENS, AND COMBINATIONS THEREOF AS BIOTHERAPEUTICS | February 2020 | July 2023 | Abandon | 42 | 2 | 1 | No | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PAPCIAK, SHARON M.
With a 18.2% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 13.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner PAPCIAK, SHARON M works in Art Unit 1651 and has examined 484 patent applications in our dataset. With an allowance rate of 48.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.
Examiner PAPCIAK, SHARON M's allowance rate of 48.3% places them in the 11% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by PAPCIAK, SHARON M receive 2.79 office actions before reaching final disposition. This places the examiner in the 81% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by PAPCIAK, SHARON M is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +24.9% benefit to allowance rate for applications examined by PAPCIAK, SHARON M. This interview benefit is in the 71% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 16.8% of applications are subsequently allowed. This success rate is in the 14% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 22.2% of cases where such amendments are filed. This entry rate is in the 28% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 57.1% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 48% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 66.7% of appeals filed. This is in the 47% percentile among all examiners. Of these withdrawals, 63.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 75.3% are granted (fully or in part). This grant rate is in the 81% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.6% of allowed cases (in the 62% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.7% of allowed cases (in the 66% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.